ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 84 citations in OpenAlex.
- CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.Frontiers in immunology · 2026Review
- Shaping viral immunotherapy towards cancer-targeted immunological cell death.Frontiers in oncology · 2025Review
- CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells.Nature communications · 2022Article
- Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses.Frontiers in molecular biosciences · 2022Review
- Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.Frontiers in bioengineering and biotechnology · 2022Article
- Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5Viruses · 2021Article
- Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors.Cell reports. Medicine · 2021Article
- Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells.Frontiers in oncology · 2021Article
- Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.Frontiers in immunology · 2021Review
- How Can We Engineer CAR T Cells to Overcome Resistance?Biologics : targets & therapy · 2021Review
- Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.Cancers · 2020Review
- Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade.Cancer immunology, immunotherapy : CII · 2020Article
- Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.Cancer cell · 2018Article
- Genetically engineered T cells for cancer immunotherapy.Signal transduction and targeted therapyReview
- New Therapeutic Options for Advanced Hepatocellular Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Erratum for
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.